Yazan Madanat

34PUBLICATIONS
259CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Medical molecular engineering of nucleic acids and proteinsGene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Natural language processing
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (34)

|Jul 28, 2026
OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML.

|Jul 03, 2026
Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

|Jul 02, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

|Jun 29, 2026
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

|Jun 02, 2026
Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia.

|Apr 07, 2026
Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes.

Amer M Zeidan, Valeria Santini, María Díez-Campelo

Pageof 6

Frequent Collaborators

9 joint publications

Joshua Zeidner

7 joint publications

Alice S Mims

7 joint publications

Tara L Lin

5 joint publications

Brian J Druker